Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Performed at Manuel Fajardo Surgical Clinical University Hospital in Havana, Cuba from September 2014 to April 2018, following a proof of concept open label study, with no control group in 20 patients diagnosed histologically in Fajardo Hospital or Oncology Institute, as Melanoma, primary cutaneous stage IIB-IIIA. All received conventional surgical treatment and oral Oncoxin-Viusid (25 ml 2 times a day for one year), where it was also indicated adjuvant treatment or chemotherapy. All were evaluated monthly the first year and semesterly the second year. Complying with the provisions of the Helsinki Act.

Inclusion criteria

• Patients with histological diagnosis of Malignant Cutaneous Melanoma in stage IIB-IIC-IIIA
• Subjects of 18 years and over of both sexes.
• General health status according to the Karnofsky Index ≥ 70.
• Laboratory parameters within the normal limits defined as: Hematopoietic: Hemoglobin ≥ 9 g / L, Total Leukocytes ≥ 3 x 109 cells / L, Neutrophils ≥ 1.5 x 109 cells / L, Platelets ≥ 100 x 109 / L Hepatic: Liver function within 2.5 times upper normal limit and without liver disease demonstrated by TGP, OGT and alkaline phosphatase.
• Patients who express written voluntariness to enter the study with their signature of the informed consent document.
• Women of childbearing age should have a negative pregnancy test and use effective contraceptive methods such as intrauterine devices, hormonal contraceptives, barrier method or tubal ligation.

Exclusion criteria

• Pregnancy or lactation.
• Patients with a second concomitant tumor.
• Present an associated chronic disease in the decompensation phase (heart disease, diabetes, hypertension).
• History of hypersensitivity to another similar product.
• Severe acute allergic states.
• Severe septic processes.
• Non-operated patients, in whom the surgery was contraindicated.
• Patients at potential risk of not completing the study (those who will travel during the period of the investigation or distance in their residence, outside the city).
• Subjects who are participating in another clinical trial.
• Patients with cognitive disorders or a mental disorder that hinders their follow-up.